FdaApplication
NDA 021346
Identifiers
- fda_app_no: NDA021346
Properties
| Property | Value |
|---|---|
| applicant_name | JANSSEN PHARMACEUTICALS INC |
| application_type | NDA |
| approval_date | 2003-10-29 |
Revenue by product
RISPERDAL CONSTA
| Period | Revenue |
|---|---|
| Q4 2022 | $1.0M |
| Q3 2022 | $119.0M |
| Q2 2022 | $125.0M |
| Q1 2022 | $129.0M |
| Q4 2021 | $-228.0M |
| Q3 2021 | $140.0M |
| Q2 2021 | $155.0M |
| Q1 2021 | $157.0M |
| Q4 2020 | $167.0M |
| Q3 2020 | $152.0M |
| Q2 2020 | $153.0M |
| Q1 2020 | $170.0M |
| Q4 2019 | $160.0M |
| Q3 2019 | $167.0M |
| Q2 2019 | $182.0M |
| Q1 2019 | $179.0M |
| Q4 2018 | $178.0M |
| Q3 2018 | $175.0M |
| Q2 2018 | $188.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (4)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| RISPERDAL CONSTA | RISPERIDONE | 12.5MG/VIAL | POWDER;INTRAMUSCULAR |
| RISPERDAL CONSTA | RISPERIDONE | 25MG/VIAL | POWDER;INTRAMUSCULAR |
| RISPERDAL CONSTA | RISPERIDONE | 37.5MG/VIAL | POWDER;INTRAMUSCULAR |
| RISPERDAL CONSTA | RISPERIDONE | 50MG/VIAL | POWDER;INTRAMUSCULAR |
4 products